Research Analysts’ Price Target Changes for November 6th (ACVA, ADNT, ADPT, ALL, APP, ARM, BOOT, BSY, CGBD, CHH)

Research Analysts’ price target changes for Thursday, November 6th:

ACV Auctions (NASDAQ:ACVA) had its target price lowered by JPMorgan Chase & Co. from $18.00 to $11.00. They currently have an overweight rating on the stock.

Adient (NYSE:ADNT) had its target price reduced by JPMorgan Chase & Co. from $26.00 to $24.00. The firm currently has a neutral rating on the stock.

Adaptive Biotechnologies (NASDAQ:ADPT) had its target price increased by JPMorgan Chase & Co. from $17.00 to $20.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Allstate (NYSE:ALL) had its target price boosted by JPMorgan Chase & Co. from $254.00 to $260.00. The firm currently has an overweight rating on the stock.

AppLovin (NASDAQ:APP) had its target price raised by JPMorgan Chase & Co. from $425.00 to $650.00. They currently have a neutral rating on the stock.

ARM (NASDAQ:ARM) had its price target increased by JPMorgan Chase & Co. from $175.00 to $180.00. They currently have an overweight rating on the stock.

Boot Barn (NYSE:BOOT) had its target price increased by JPMorgan Chase & Co. from $276.00 to $282.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Bentley Systems (NASDAQ:BSY) had its price target cut by JPMorgan Chase & Co. from $56.00 to $51.00. They currently have a neutral rating on the stock.

Carlyle Secured Lending (NASDAQ:CGBD) had its target price reduced by JPMorgan Chase & Co. from $12.50 to $12.00. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Choice Hotels International (NYSE:CHH) had its target price boosted by JPMorgan Chase & Co. from $99.00 to $102.00. The firm currently has an underweight rating on the stock.

Chime Financial (NASDAQ:CHYM) had its price target cut by JPMorgan Chase & Co. from $40.00 to $34.00. The firm currently has an overweight rating on the stock.

Cinemark (NYSE:CNK) had its price target cut by JPMorgan Chase & Co. from $38.00 to $37.00. They currently have an overweight rating on the stock.

CONMED (NYSE:CNMD) had its target price reduced by JPMorgan Chase & Co. from $58.00 to $52.00. The firm currently has a neutral rating on the stock.

Corpay (NYSE:CPAY) had its price target trimmed by JPMorgan Chase & Co. from $400.00 to $350.00. They currently have an overweight rating on the stock.

Charles River Laboratories International (NYSE:CRL) had its target price raised by JPMorgan Chase & Co. from $160.00 to $165.00. The firm currently has a neutral rating on the stock.

Centuri (NYSE:CTRI) had its price target boosted by JPMorgan Chase & Co. from $20.00 to $22.00. The firm currently has an underweight rating on the stock.

Clearwater Analytics (NYSE:CWAN) had its target price cut by JPMorgan Chase & Co. from $28.00 to $26.00. The firm currently has an overweight rating on the stock.

DoorDash (NASDAQ:DASH) had its target price reduced by JPMorgan Chase & Co. from $325.00 to $300.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Duolingo (NASDAQ:DUOL) had its price target trimmed by JPMorgan Chase & Co. from $465.00 to $300.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Establishment Labs (NASDAQ:ESTA) had its price target increased by JPMorgan Chase & Co. from $45.00 to $71.00. They currently have an overweight rating on the stock.

Eaton (NYSE:ETN) had its target price boosted by JPMorgan Chase & Co. from $429.00 to $440.00. They currently have an overweight rating on the stock.

Fair Isaac (NYSE:FICO) had its target price boosted by JPMorgan Chase & Co. from $1,750.00 to $1,825.00. The firm currently has a neutral rating on the stock.

Fair Isaac (NYSE:FICO) had its target price reduced by Jefferies Financial Group Inc. from $2,150.00 to $2,100.00. Jefferies Financial Group Inc. currently has a buy rating on the stock.

Amicus Therapeutics (NASDAQ:FOLD) had its price target boosted by JPMorgan Chase & Co. from $18.00 to $19.00. They currently have an overweight rating on the stock.

Fortinet (NASDAQ:FTNT) had its price target lowered by Jefferies Financial Group Inc. from $85.00 to $80.00. The firm currently has a hold rating on the stock.

GXO Logistics (NYSE:GXO) had its target price boosted by JPMorgan Chase & Co. from $66.00 to $67.00. The firm currently has an overweight rating on the stock.

HubSpot (NYSE:HUBS) had its target price trimmed by Jefferies Financial Group Inc. from $650.00 to $560.00. The firm currently has a buy rating on the stock.

Iron Mountain (NYSE:IRM) had its target price raised by JPMorgan Chase & Co. from $100.00 to $111.00. They currently have an overweight rating on the stock.

OPENLANE (NYSE:KAR) had its price target increased by JPMorgan Chase & Co. from $28.00 to $29.00. They currently have a neutral rating on the stock.

New York Times (NYSE:NYT) had its price target increased by JPMorgan Chase & Co. from $70.00 to $71.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Open Text (NASDAQ:OTEX) (TSE:OTC) had its price target raised by Jefferies Financial Group Inc. from $33.00 to $35.00. Jefferies Financial Group Inc. currently has a hold rating on the stock.

Paycom Software (NYSE:PAYC) had its price target trimmed by Jefferies Financial Group Inc. from $225.00 to $190.00. They currently have a hold rating on the stock.

Penumbra (NYSE:PEN) had its target price raised by JPMorgan Chase & Co. from $265.00 to $275.00. The firm currently has a neutral rating on the stock.

Insulet (NASDAQ:PODD) had its target price increased by Jefferies Financial Group Inc. from $375.00 to $400.00. They currently have a buy rating on the stock.

Pattern Group (NASDAQ:PTRN) had its price target increased by JPMorgan Chase & Co. from $18.00 to $21.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Revolution Medicines (NASDAQ:RVMD) had its target price increased by JPMorgan Chase & Co. from $71.00 to $82.00. The firm currently has an overweight rating on the stock.

RxSight (NASDAQ:RXST) had its target price increased by JPMorgan Chase & Co. from $8.00 to $9.00. JPMorgan Chase & Co. currently has an underweight rating on the stock.

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by JPMorgan Chase & Co. from $26.00 to $28.00. They currently have an overweight rating on the stock.